...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of gastroenterology and hepatology >Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test.
【24h】

Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test.

机译：慢性病毒性肝炎的干扰素治疗过程中的抑郁症：通过计算机化验早期发现有风险的患者。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: At the doses used for the treatment of chronic viral hepatitis, interferon (IFN)-related side-effects are usually modest, even though in some cases they require the interruption of therapy. Neuropsychiatric disturbances that range from modest depression and irritability to forms of manic-depressive psychosis and attempted or successful suicides are among the most important side-effects. The aim of our study was to determine whether the Minnesota Multiphasic Personality Inventory (MMPI) is a sensitive and reliable test for the early identification of patients at risk of depression before IFN therapy is commenced, and whether it could be useful for the monitoring of these patients during treatment. METHODS: We prospectively studied 67 patients with chronic active liver diseases, consecutively enrolled in open studies and treated with r-IFNalpha2. Before starting therapy and after 3 months of treatment, all patients underwent a clinical neurological evaluation and MMPI. RESULTS: At baseline, the correlation between the clinical evaluation and the score of the depression scale of the MMPI was statistically significant (P< 0.0001). Nine of 14 (64.3%) patients with a baseline score > or = 60/100 showed a depressive mood after 3 months of therapy. Five of 44 patients (11.3%) with a baseline score < 60/100 showed a depression of medium level after 3 months of treatment. This difference was highly significant (P< 0.0001). CONCLUSIONS: According to our results, the MMPI is a reliable and sensitive test for the early identification of patients at risk of depression before and during IFN therapy for chronic viral liver diseases.
机译：目的：在用于治疗慢性病毒性肝炎的剂量下，干扰素（IFN）相关的副作用通常不大，即使在某些情况下需要中断治疗。从轻度抑郁和易怒到躁狂抑郁性精神病以及未遂或未遂自杀的神经精神障碍都是最重要的副作用。我们研究的目的是确定明尼苏达州多相性人格量表（MMPI）是否是一种灵敏可靠的测试方法，可用于在IFN治疗开始之前及早发现患有抑郁风险的患者，以及该方法是否可用于监测这些患者患者在治疗期间。方法：我们前瞻性研究了67例慢性活动性肝病患者，连续参加了公开研究并用r-IFNalpha2治疗。在开始治疗之前和治疗3个月后，所有患者均接受了临床神经系统评估和MMPI。结果：在基线时，临床评估与MMPI抑郁量表得分之间的相关性具有统计学意义（P <0.0001）。治疗3个月后，基线评分>或= 60/100的14例患者中有9例（64.3％）表现出抑郁情绪。基线评分<60/100的44例患者中有5例（11.3％）在治疗3个月后表现出中等水平的抑郁。这种差异是非常显着的（P <0.0001）。结论：根据我们的结果，MMPI是一种可靠且灵敏的测试，可用于早期识别在慢性病毒性肝病的IFN治疗之前和治疗期间有抑郁风险的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号